# Advancing Heart Failure Care: Breakthroughs and Emerging Strategies

## TL;DR

This paper reviews recent breakthroughs in heart failure treatment, including new drugs and interventions that improve care and outcomes.

## Contribution

The paper highlights novel therapeutic agents and interventions across the heart failure care continuum.

## Key findings

- Finerenone provides cardiorenal benefits in patients with diabetes and chronic kidney disease.
- Glucagon-like peptide-1 receptor agonists show promise for heart failure with preserved or mildly reduced ejection fraction.
- Transcatheter interventions for tricuspid regurgitation and total artificial heart systems offer new treatment options.

## Abstract

Heart failure represents a complex clinical syndrome characterized by progressive ventricular dysfunction, systemic congestion, and high mortality despite significant advances in pharmacological and device-based therapy. This review explores recent developments across the heart failure continuum, with a focus on therapeutic advances across the continuum of care, with emphasis on both established and emerging strategies. In patients with reduced ejection fraction, early initiation of the four pillars markedly lowers cardiovascular events, yet real-world implementation remains limited by therapeutic inertia and underdosing. Novel agents such as finerenone provide cardiorenal benefits in patients with diabetes and chronic kidney disease, while glucagon-like peptide-1 receptor agonists show promise in preserved or mildly reduced ejection fraction, particularly with obesity. Tricuspid regurgitation, once considered a secondary phenomenon, is now recognized as a modifiable contributor to disease progression, with transcatheter interventions offering new therapeutic avenues. In advanced disease, innovations including donation after circulatory death and the development of total artificial heart systems offer promising solutions to overcome organ shortages and improve access to transplantation. Together, these advances highlight a shift toward precision-guided, multidisciplinary heart failure care.